Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00791778 · ClinicalTrials.gov registry record · Phase 2
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
A Phase 2 study of Ovarian Neoplasms, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 246
- Enrollment target
- 20
- Study locations
NCT00791778: Completed Phase 2 study of Ovarian Neoplasms, sponsored by Bayer.
NCT00791778 is a Phase 2 study of Ovarian Neoplasms that has completed, run by Bayer. The registered enrollment target is 246 participants, below the 361-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (32% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00791778, a Phase 2 study of Ovarian Neoplasms, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 246 participants
- Enrollment target
- 20
- Study locations
Study Summary
Comparison of Nexavar with a placebo as maintenance therapy for patients with advanced Ovarian or primary Peritoneal cancers in complete remission following surgery and one regimen of chemotherapy.
Primary Outcome
Time from randomization to the first documented disease progression by radiological or pathologic assessment or death due to any cause whichever occurred first. For patients who had not progressed or died at the time of analysis, PFS was censored at the date of their last evaluable tumor scan.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sorafenib (Nexavar, BAY43-9006)
Study Locations (20)
Other
- - Bruxelles - Brussel
- - Bruxelles - Brussel
- - Edegem
- - La Louvière
- - Leuven
- - Wilrijk
- - Jyväskylä
- - Kuopio
- - Angers
- - Caen
- - Lyon
- - Tours
Ontario
- - Hamilton
- - London
- - Toronto
California
- - La Jolla
Florida
- - Jacksonville
Georgia
- - Augusta
Maine
- - Scarborough
Quebec
- - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2008-11 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
What the finished NCT00791778 record still lists
NCT00791778 is an interventional study that assigns participants to a tested intervention. The registered 246 participants enrollment target is mid-sized for trials with a published cap, below the 361-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (32% lower).
The record links to 1 condition, with Ovarian Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00791778 names 20 study sites across 7 states, led by Other, Ontario, California.
Frequently Asked Questions
What is clinical trial NCT00791778 about?
NCT00791778 is a clinical study titled "Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer". Comparison of Nexavar with a placebo as maintenance therapy for patients with advanced Ovarian or primary Peritoneal cancers in complete remission following surgery and one regimen of chemotherapy.
What is the current status of trial NCT00791778?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 246 participants. The study started on 2008-11. Estimated completion is 2012-12.
What conditions does trial NCT00791778 study?
This clinical trial studies the following conditions: Ovarian Neoplasms.
What interventions are being tested in trial NCT00791778?
The interventions under investigation include: Placebo (DRUG), Sorafenib (Nexavar, BAY43-9006) (DRUG).
Who is sponsoring clinical trial NCT00791778?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00791778 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Maine, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00791778's enrollment target sits among peer trials
246 16th of 38 higher than 23 of 38 other Ovarian Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
RECRUITING · Phase 2
-
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Trial of Vigil for Participants With Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
COMPLETED · Phase 2
-
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04973605 · 246 participants · Phase 1
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- NCT06395168 · 246 participants · NA
Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination
- NCT07048769 · 246 participants · Phase 4
Paracervical Block for Pain Reduction in Saline Infusion Sonograms
- NCT07176650 · 246 participants · Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia